Key Takeaways
- •PRAME, or Preferentially Expressed Antigen in Melanoma, is a cancer-testis antigen (CTA) encoded on chromosome 22, among several genes for immunoglobulin proteins.
- •Cancers that show PRAME overexpression include cutaneous and uveal melanoma, non-melanoma skin cancer, Merkel cell carcinoma, acute myeloid leukemia, breast and ovarian cancer, non-small cell lung cancer (NSCLC), and neuroblastoma.
- •PRAME contributes to tumor development through several mechanisms.
PRAME: A Selective Biomarker in Cancer Immunotherapy
PRAME, or Preferentially Expressed Antigen in Melanoma, is a cancer-testis antigen (CTA) encoded on chromosome 22, among several genes for immunoglobulin proteins. Its expression is normally restricted to the testis, ovary, placenta, and at low levels in adrenal and endometrial tissues. This limited expression in healthy adult tissues makes PRAME an attractive target for T-cell-based immunotherapy, as it is overexpressed in a wide range of malignancies.
Cancers that show PRAME overexpression include cutaneous and uveal melanoma, non-melanoma skin cancer, Merkel cell carcinoma, acute myeloid leukemia, breast and ovarian cancer, non-small cell lung cancer (NSCLC), and neuroblastoma. This restricted expression profile positions PRAME as a prime candidate for targeted immunotherapy approaches.
Biological Functions in Tumorigenesis
PRAME contributes to tumor development through several mechanisms. It represses retinoic acid signaling, which blocks differentiation and promotes proliferation. It also promotes epithelial-to-mesenchymal transition (EMT), a process where cells lose adhesion to neighboring cells, increase motility, and gain migration potential. Additionally, PRAME helps form an immunosuppressive ("cold") tumor microenvironment by increasing checkpoint expression and reducing antigen presentation.
These functions highlight PRAME's role in driving malignancy and immune evasion, making it a critical target for therapeutic intervention.
Diagnostic and Prognostic Utility
PRAME is often strongly expressed in primary and metastatic melanomas but absent or weakly expressed in benign nevi. This makes it a highly sensitive (greater than 90%) and specific marker for melanocytic lesions. Increased PRAME expression is associated with a poorer prognosis in melanomas and other malignancies.
In hematologic malignancies, the prognostic impact is mixed. PRAME overexpression is linked to poor prognosis in diffuse large B-cell lymphoma, Hodgkin's lymphoma, multiple myeloma, and chronic leukemia. However, in pediatric B-cell acute lymphoblastic leukemia, higher PRAME levels have been associated with better outcomes. This dual role highlights the need for context-dependent interpretation of PRAME expression.
Therapeutic Strategies in Development
Several immunotherapies targeting PRAME are in development. These include PRAME-targeted peptide vaccines, adoptive T-cell therapy with PRAME-specific tumor-infiltrating lymphocytes (TILs), and therapy with T-cell receptor-engineered T cells. Unlike CAR T cells, TCR-engineered T cells can recognize intracellular antigens presented by major histocompatibility complex (MHC) molecules. PRAME-CD3+ bispecific molecules are also being explored.
For researchers, ready-to-use PRAME peptide pools are available for T-cell assays, supporting translational research and clinical immunomonitoring. These peptides include specific HLA-restricted sequences such as PRAME 100-108 (HLA-A02:01), PRAME 425-433 (HLA-A02:01), PRAME 300-309 (HLA-A02:01), PRAME 301-309 (HLA-A24), PRAME 254-262 (HLA-A24), and PRAME 242-251 (HLA-A03). Custom peptide synthesis is also available for tailored sequences and HLA contexts.
Challenges and Innovative Strategies
Despite its promise, PRAME-targeted therapy faces several challenges. Tumor heterogeneity can limit the effectiveness of single-target approaches. The use of demethylating agents to artificially upregulate PRAME is one strategy to overcome this. The cold tumor microenvironment is another hurdle, addressed by combining cancer vaccines with checkpoint inhibitors such as nivolumab and ipilimumab.
Downregulation of HLA-I molecules on tumor cells can also impede T-cell recognition. Co-treatment with MEK inhibitors or epigenetic drugs may restore antigen presentation. These combination strategies are at the forefront of precision immuno-oncology research.
Practical Research Considerations
For researchers working with PRAME peptides, understanding the specific HLA context is crucial for assay design and therapeutic development. Our Peptide Glossary provides definitions for key terms like HLA, T-cell receptor, and bispecific molecules. Additionally, the Reconstitution Calculator can help ensure accurate peptide preparation for in vitro studies.
Conclusion
PRAME is a versatile biomarker and therapeutic target due to its selective tumor expression, functional roles in malignancy, and emerging clinical applications. Current efforts focus on overcoming immune evasion and tumor heterogeneity through combination therapies and epigenetic modulation. Researchers interested in PRAME peptide research can explore our latest peptide news for updates on clinical trials and preclinical studies.
Frequently Asked Questions
Q: What does peptide therapy mean in peptide research?
A: In peptide research, peptide therapy refers to the use of specific peptide sequences to modulate biological pathways, such as targeting cancer-testis antigens like PRAME. These peptides can be used as vaccines to stimulate T-cell responses or as tools to study antigen presentation and immune recognition in vitro.
Q: Which Volta resources help verify peptide therapy?
A: Volta Peptides offers several tools to support peptide therapy research. The [Purity Analyzer](/tools/peptide-purity-calculator) helps verify peptide quality via COA data, while the [Stability Calculator](/tools/peptide-storage-guide) aids in determining optimal storage conditions. The [Peptide Glossary](/tools/peptide-glossary) provides definitions for key immunotherapy terms.
Q: How is PRAME expression detected in research?
A: PRAME expression is typically detected using immunohistochemistry, RT-PCR, or RNA sequencing. Its strong expression in primary and metastatic melanomas versus benign nevi makes it a highly sensitive (greater than 90%) and specific diagnostic marker.
Q: What are the main therapeutic strategies targeting PRAME?
A: The main strategies include PRAME-targeted peptide vaccines, adoptive T-cell therapy with PRAME-specific TILs, TCR-engineered T cells, and PRAME-CD3+ bispecific molecules. These approaches aim to use the immune system to recognize and eliminate PRAME-expressing tumor cells.
Q: Why is PRAME considered a cancer-testis antigen?
A: PRAME is classified as a cancer-testis antigen because its expression is normally restricted to immune-privileged sites like the testis and ovary, but it is aberrantly overexpressed in many cancers. This restricted normal expression makes it a safe and specific target for immunotherapy.